- Home
- LU vs RCUS Comparison
LU vs RCUS Comparison
Compare LU & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LU | RCUS |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LU | RCUS |
|---|---|---|
| Price | $1.89 | $22.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $30.27 |
| AVG Volume (30 Days) | ★ 1.5M | 892.5K |
| Earning Date | 03-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.52 | $83.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.73 | $7.06 |
| 52 Week High | $4.57 | $26.40 |
Technical Indicators
Market Signals| Indicator | LU | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 51.85 |
| Support Level | $1.73 | $20.18 |
| Resistance Level | $2.77 | $24.33 |
| Average True Range (ATR) | 0.08 | 1.09 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 40.51 | 66.52 |
Price Performance
Historical ComparisonAbout LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.